Company Overview

MDxHealth SA is a precision diagnostics company focused on developing and commercializing molecular diagnostic tests for urologic cancers, primarily prostate cancer. The company operates in the molecular diagnostics and clinical genomics industries, with a business model centered on epigenetic and genomic biomarker testing that supports clinical decision-making. Its primary revenue is generated from proprietary urine- and tissue-based tests used to assess prostate cancer risk, detection, and disease management, with customers consisting mainly of urologists, integrated health systems, and clinical laboratories.

The company’s core products include SelectMDx, ConfirmMDx, and MonitorMDx, which are designed to improve diagnostic accuracy, reduce unnecessary biopsies, and guide patient management. MDxHealth differentiates itself through clinically validated epigenetic biomarkers, reimbursement coverage from U.S. payors, and integration into urology clinical workflows. Founded in Belgium in 2003, the company originally focused on epigenetic cancer diagnostics before transitioning its operational headquarters and commercial focus to the United States, where it now derives the majority of its revenue.

Business Operations

MDxHealth operates primarily through its molecular diagnostics business, which encompasses the development, validation, and commercialization of prostate cancer tests. Revenue is largely generated from test volumes processed through the company’s U.S.-based laboratory operations, with reimbursement obtained from private insurers, Medicare, and other payors. The company’s operations are organized around its proprietary diagnostic test portfolio rather than formally disclosed operating segments.

The company conducts most commercial activities through its U.S. subsidiary, MDxHealth Inc., which manages sales, reimbursement, and laboratory services. Research and development activities focus on expanding clinical evidence, improving test performance, and developing next-generation diagnostic assays. MDxHealth maintains collaborations with academic institutions and clinical partners to support validation studies and guideline inclusion, while retaining ownership of its core epigenetic technologies and intellectual property.

Strategic Position & Investments

MDxHealth’s strategic direction is centered on expanding adoption of its prostate cancer diagnostics in the U.S. market, increasing reimbursement coverage, and improving operating leverage through higher test volumes. Growth initiatives include broader physician adoption, inclusion in clinical guidelines, and deeper penetration into integrated delivery networks and large urology practices. The company has also emphasized real-world evidence generation to support payor coverage decisions.

Historically, MDxHealth has pursued selective acquisitions and licensing of complementary diagnostic technologies to strengthen its product portfolio, though its recent strategy has focused more on organic growth and commercialization of existing assays. The company continues to invest in emerging molecular diagnostic approaches, including epigenetic and genomic risk stratification tools, to support earlier detection and more personalized management of prostate cancer.

Geographic Footprint

MDxHealth’s operational headquarters are located in North America, with its principal executive offices and laboratory operations based in the United States, specifically in California. The U.S. represents the company’s most significant market by revenue, driven by reimbursement access and the size of the urology care market.

The company retains a historical and corporate presence in Europe, reflecting its origins in Belgium, though European commercial activity is limited compared to the U.S. MDxHealth’s products have international visibility through clinical studies and limited distribution, but the company’s primary operational and financial influence is concentrated in the U.S. healthcare system.

Leadership & Governance

MDxHealth is led by an executive team with experience in molecular diagnostics, life sciences commercialization, and clinical research. The leadership team emphasizes evidence-based medicine, disciplined commercialization, and alignment with clinical guidelines as core elements of the company’s strategic vision.

Key executives include:

• Michael McGarrity – Chief Executive Officer
• Jack Schalken – Chief Scientific Officer

The company is governed by a board of directors with backgrounds in healthcare, diagnostics, and public company governance. MDxHealth’s leadership philosophy focuses on translating validated science into reimbursable clinical solutions while maintaining regulatory compliance and financial discipline as a publicly traded company.